79433-95-7

Usage

Uses

Used in Pharmaceutical Synthesis:
N-CBZ-TRANS-4-HYDROXY-D-PROLINE METHYL ESTER is used as an intermediate in the production of peptide-based pharmaceuticals. Its unique structure allows for the synthesis of complex organic molecules, contributing to the development of new drugs and therapeutic agents.
Used in Research and Development:
In the field of research and development, N-CBZ-TRANS-4-HYDROXY-D-PROLINE METHYL ESTER serves as a valuable compound for the exploration and creation of novel organic compounds. Its versatility enables scientists to investigate its potential applications in various chemical reactions and processes, further expanding the horizons of medicinal and organic chemistry.
Used in Medicinal Chemistry:
N-CBZ-TRANS-4-HYDROXY-D-PROLINE METHYL ESTER is utilized in medicinal chemistry for the synthesis of bioactive molecules and the development of new drug candidates. Its unique properties and reactivity make it an essential component in the design and synthesis of pharmaceutical compounds with potential therapeutic applications.
Used in Organic Chemistry:
In organic chemistry, N-CBZ-TRANS-4-HYDROXY-D-PROLINE METHYL ESTER is employed as a key building block for the synthesis of various organic compounds. Its functional groups and protecting group allow for selective reactions and the formation of complex molecular structures, making it a valuable asset in the synthesis of organic molecules with diverse applications.

InChI:InChI:1S/C14H17NO5/c1-19-13(17)12-7-11(16)8-15(12)14(18)20-9-10-5-3-2-4-6-10/h2-6,11-12,16H,7-9H2,1H3

Upstream product

• 618-28-0 trans-4-hydroxy-D,L-proline 
• 501-53-1 benzyl chloroformate 
• 186581-53-3 diazomethane 
• 155153-78-9 (4S)-1-[(benzyloxy)carbonyl]-4-hydroxy-D-proline 
• 67-56-1 methanol 
• 155075-23-3 (2R,4R)-1-benzyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate 
• 3398-22-9 trans-4-hydroxyproline 
• 130930-25-5 (R,R)-4-hydroxy-1-(benzyloxycarbonyl)pyrrolidine-2-carboxylic acid 
• 51-35-4 4R-4-hydroxyproline 

Downstream Products

• 1269622-56-1 (2R,4S)-4-(tert-butyl-dimethyl-silanyloxy)-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 
• 1269622-57-2 (2R,4S)-4-(tert-butyl-dimethyl-silanyloxy)-2-hydroxymethyl-pyrrolidine-1-carboxylic acid benzyl ester 
• 1269622-58-3 (2R,4S)-4-(tert-butyl-dimethyl-silanyloxy)-2-formyl-pyrrolidine-1-carboxylic acid benzyl ester 
• 1269622-59-4 (2R,4S)-4-(tert-butyl-dimethyl-silanyloxy)-2-[hydroxy-(1,3,5-trimethyl-1H-pyrazol-4-yl)-methyl]-pyrrolidine-1-carboxylic acid benzyl ester 
• 1269622-60-7 (2S,4S)-4-(tert-butyl-dimethyl-silanyloxy)-2-(1,3,5-trimethyl-1H-pyrazol-4-ylmethyl)-pyrrolidine-1-carboxylic acid benzyl ester 
• 1269622-61-8 (2S,4S)-4-hydroxy-2-(1,3,5-trimethyl-1H-pyrazol-4-ylmethyl)-pyrrolidine-1-carboxylic acid benzyl ester 
• 1269622-64-1 (2R,4S)-4-(tert-butyl-dimethyl-silanyloxy)-2-[phenoxythiocarbonyloxy-(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]-pyrrolidine-1-carboxylic acid benzyl ester 
• 1269622-71-0 (2S,4R)-4-fluoro-2-(1,3,5-trimethyl-1H-pyrazol-4-ylmethyl)-pyrrolidine-1-carboxylic acid benzyl ester 
• 79775-07-8 4S-O⁴(t-butyl)-D-Pro acid 
• 268729-12-0 4S-O⁴(t-butyl)-N₁-(fluorenylmethyloxycarbonyl)-D-proline 
• 787615-46-7 (2R,4S)-N-1-(benzyloxycarbonyl)-4-(p-toluenesulfonyloxy)proline methyl ester 
• 340981-85-3 benzoic acid 2-({2-[2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-pyrrolidin-1-yl]-acetylamino}-methyl)-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-3-yl ester 
• 340981-86-4 2-[2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-pyrrolidin-1-yl]-N-[3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-2-ylmethyl]-acetamide 
• 340981-83-1 [(2R,4R)-2-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-pyrrolidin-1-yl]-acetic acid ethyl ester 

Relevant academic research and scientific papers

ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES

The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications

Spiegelmeric 4R/S-hydroxy/amino-L/D-prolyl collagen peptides: conformation and morphology of self-assembled structures

The primary structure of collagen, the major protein in connective tissue of mammals, comprises of repeating triads [(LPro-LHyp-Gly)n, P1, LHyp being 4R-hydroxy-lProline)] in a single strand that adopts left-handed polyproline II type helix. Three such single stranded helices wind around each another and held together by interchain H-bonds to form right-handed triple helix. This manuscript reports on collagen derived from its mirror image triad [(DPro-DHyp-Gly)n, P2, DHyp being 4S-hydroxy-DProline) and its 4-amino analogue (DPro-DAmp-Gly)n P4, DAmp being 4S-amino-DProline that form corresponding spiegelmeric triplexes. The amino L-collagen peptide (LPro-LAmp-Gly)n P3 and its D-analogue P4 show higher thermal stabilities compared to 4-hydroxy-lProline collagen peptides P1 and P2. The enantiomeric peptide pairs show mirror image CD profiles and identical thermal stability, with ionizable 4-amino group in P3 and P4 imparting pH dependent triplex stability. Upon cold mixing of the L- and D-collagen peptides, different morphological nanostructures arise from inter triplex peptide association. When the peptides are hot mixed (annealed), the inter peptide association occurs via interaction of single stranded peptide chains of opposite handedness leading to networked gel formation in P1 and P2, while the charged peptides P3 and P4 show more ordered nanofibers, different from the enantiomerically pure peptides. The nanocomposites of such chiral hybrid peptides may have not only interesting physicomorphology, but also biological properties that need exploration.

DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE

Provided herein are a dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B. Specifically, provided herein is a compound having Formula (I) or (Ia), or a stereisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.

Dihydropyridine compound and application thereof to drugs

The invention relates to a dihydropyridine compound and application of the dihydropyridine compound serving as a drug, in particular to application of the dihydropyridine compound serving as a drug for treating and preventing hepatitis B. Specifically, the invention relates to the compound shown as the general formula (I) or (Ia) (please see the specifications for the general formula (I) or (Ia))or stereoisomers, tautomer, a nitrogen oxide, solvate, metabolites and medically acceptable salt of the compound or a prodrug of the compound, wherein all variables are defined in the specification. The invention further relates to application of the compound shown as the general formula (I) or (Ia) or enantiomers, non-enantiomers, the tautomer, hydrates, the solvate or the medically acceptable salt of the compound serving as drugs, in particular to application of the compound or the enantiomers, the non-enantiomers, the tautomer, the hydrates, the solvate or the medically acceptable salt of the compound serving as the drugs for treating and preventing hepatitis B.

HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES

The present teachings relate to compounds of Formula (I): and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, R4, R5, ring A, and Z are as defined herein

Hydroxamate-Based Inhibitors of Deacetylases

The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, R4, R5, ring A, and Z are as defined herein.

AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE

The invention relates to azabenzofuranyl compounds of Formula (I) with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzofuranyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

Synthesis of trans-L/D-2-(tert-butoxycarbonylaminomethyl)-4-(thymin-1-yl) pyrrolidin-1-yl acetic acid

To delineate the binding preferences of stereochemically divergent pyrrolidine PNAs, synthesis of all four diastreomeric monomers of I and the systematic complexation studies of the resultant PNAs with complementary DNA/ RNA is essential. We herein report the synthesis of trans-L/D-2-(tert-butoxycarbonylaminomethyl)-4-(thymin-1-yl) pyrrolidin-1-yl acetic acids I, their incorporation in PNA oligomers and DNA binding studies will be presented.

Nucleosides and Oligonucleotides Derived from trans-4-Hydroxy-N-acetylprolinol

The 4-O-phosphoramidites of monomethoxytritylated 4-hydroxy-N-6-benzoyladenin-9-yl)acetyl>prolinol and 4-hydroxy-N-prolinol were prepared for incorporation into nucleic acids.The L-trans all-adenine oligonucleotide (ON) hybridises to natural oligothymidylate, apparently via triplex formation.All-purine sequences of the L-trans form can also form homo-complexes with their pyrimidine counterpart.The D-trans compounds give larger destabilisation when inserted in DNA.D-trans all-adenine ONs do not form complexes with natural oligothymidylate.For this series of modified ONs no hybridisation could be detected between complementary strands of opposite enantiomeric form.